CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics Pharmaceuticals to Participate in December Investor Conferences

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:  

Evercore ISI 3rd Annual HealthCONx Conference
Date:   Thursday, December 3rd, 2020
Time:   1:00 - 1:45 pm ET in Track 1
Panel:   Easy Pills to Swallow: Oral Drugs for Large Endo Markets
Presenter:   Dr. Scott Struthers, Founder & CEO
   
Piper Sandler's 32nd Annual Healthcare Conference
Date:   Tuesday - Thursday, December 1st - 3rd, 2020
Time:   On demand
Presenter:   , Founder & CEO, and , Chief Medical Officer
Webcast:   Pre-recorded fireside chats are available for the annual on the Events section on the Company’s website as well as on the Piper Sandler conference website.

About Crinetics Pharmaceuticals 

 is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, , is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing , an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit .

Contacts:

Marc Wilson

Chief Financial Officer



(858) 450-6464

Investors / Media:

Corey Davis

LifeSci Advisors



(212) 915-2577

Aline Sherwood

Scienta Communications



(312) 238-8957



EN
23/11/2020

Underlying

CRNXCrinetics Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Resul...

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, November 6 at 4:30 p.m. ET  Domestic:1 833-470-1428International:1 646-844-6383Access Code:166837   Webcast: Participants can use the dial-in numbers abov...

9h / 21m 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the T...

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burden Launch of lead product PALSONIFY marks a pivotal milestone for Crinetics as the premier endocrine-focused global pharmaceutical company Investor call to be...

September 25, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants U...

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an aggregate of 43,800 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Ind...

September 10, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the T...

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development. “Receiving Orphan Drug Design...

August 21, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Unde...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch